IGHE and Alzheimer disease: In vivo assessments further substantiated HSN-S1’s efficacy, revealing significant reductions in AD markers, including (1) epidermal thickening, (2) transepidermal water loss (TEWL), (3) serum IgE levels, and (4) Th2 and Th17 cytokines.